First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
To our knowledge, this is the largest real-world cohort of patients treated with chemo-immunotherapy for ES-SCLC. Although one-third of patients would not have been eligible for pivotal trials, the survival outcomes in our cohort are similar to those in registrational trials. In particular, the number of long-term survivors and the safety data are comparable, supporting the use of chemo-immunotherapy as first-line treatment for ES-SCLC in daily clinical practice.
Authors
- Lindsay Hennah
- Sacha I. Rothschild (ORCID: https://orcid.org/0000-0003-1304-9340)
- Tom Newsom‐Davis
- Samantha Cox
- Lisa Holer
- Shairoz Merchant
- Raffaele Califano (ORCID: https://orcid.org/0000-0003-2611-5319)
- Christine Waibel
- Emma Rathbone
- Ferdinando Cerciello (ORCID: https://orcid.org/0000-0001-8987-5732)
- Taha Khalid (ORCID: https://orcid.org/0000-0002-5269-1160)
- Pirmin Häuptle
- Martin Früh (ORCID: https://orcid.org/0000-0002-4047-1734)
- T. Geldart (ORCID: https://orcid.org/0000-0001-6413-5789)
- Laura Moliner (ORCID: https://orcid.org/0000-0002-1532-242X)
- Stefanie Hayoz (ORCID: https://orcid.org/0000-0002-2265-6559)
- Heidi J. Gray (ORCID: https://orcid.org/0000-0002-3927-6739)
- Martina Bertschinger (ORCID: https://orcid.org/0000-0003-1736-812X)
- Catherine Handforth (ORCID: https://orcid.org/0000-0001-5171-4917)
- Michael Mark
- Samreen Ahmed (ORCID: https://orcid.org/0000-0001-8204-6122)
- Stephen Robinson (ORCID: https://orcid.org/0000-0003-0623-4636)
- Núria Zellweger (ORCID: https://orcid.org/0000-0002-3202-2365)
- Patrizia Froesch (ORCID: https://orcid.org/0000-0002-8140-1249)
- Sabine Schmid (ORCID: https://orcid.org/0000-0003-0840-3253)
- Laetitia Mauti (ORCID: https://orcid.org/0000-0002-6652-1947)
- Shradha Bhagani (ORCID: https://orcid.org/0000-0001-7251-2249)
- Deborah C Scott
- Fiona Helen Blackhall (ORCID: https://orcid.org/0000-0001-8716-3395)
- Adrienne Bettini
- Arshi Denton
- Nicola Steele
- Michael Davidson
- Veronika Blum
- Luke Nolan
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- University of Lucerne (CH)
- Velindre NHS Trust (GB)
- Chelsea and Westminster Hospital NHS Foundation Trust (GB)
- Kantonsspital St. Gallen (CH)
- Beatson West of Scotland Cancer Centre (GB)
- London North West Healthcare NHS Trust (GB)
- Poole Hospital (GB)
- University Hospital of Bern (CH)
- University Hospitals of Leicester NHS Trust (GB)
- University Hospital of Basel (CH)
- University Hospital Southampton NHS Foundation Trust (GB)
- Calderdale and Huddersfield NHS Foundation Trust (GB)
- Kantonsspital Baselland (CH)
- Ente Ospedaliero Cantonale (CH)
- Kantonsspital Winterthur (CH)
- Psychiatry Baselland (CH)
- Fribourg Development Agency (CH)
- Royal Marsden Hospital (GB)
- Réseau Fribourgeois de Santé Mentale (CH)
- Kantonsspital Baden (CH)
- The Christie NHS Foundation Trust (GB)
- Poole Hospital NHS Foundation Trust (GB)
- Swiss Group For Clinical Cancer Research (CH)
- Kantonsspital Graubünden (CH)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100744
- Citations
- 4
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.13